gsci posts

Feed

Closing Bell: A wild trading day

Today was nothing short of a wild trading day and despite the levels seen at the close it is still a toss up over whether the bulls or bears won today. Merrill Lynch has said that the commodities cycle may have peaked in the first half of this year. It noted that the S&P/GSCI commodity index was up roughly 41% during the first half of 2008, which is the largest gain since the index inception. This may have only been one factor, but oil fell as much as $9.00 per barrel in the biggest one-day dollar drop since 1991. We did even briefly see the VIX hit that magic 30.0 reading. Below are the unofficial closing bell levels:

DJIA 10,961.72 (-93.47)
S&P500 1214.96 (-13.34)
NASDAQ 2215.71 (+2.84)
10YR T-Note 3.844% (-0.036%)
52-WEEK LOWS
TOP ANALYST UPGRADES
TOP ANALYST DOWNGRADES

Genentech, Inc. (NYSE: DNA) rose today despite a weak earnings report and despite it saying it was going to act like an old industrial company with a share buyback plan. Shares were up over 5% at $79.37 in todays final minutes.

Continue reading Closing Bell: A wild trading day

Analyst initiations: North American pipeline sector, ARO and IMCL

MOST NOTEWORTHY: The North American Pipeline sector, Aeropostale and ImClone were today's noteworthy initiations:
  • BMO Capital initiated the North American Pipeline sector with a Market Perform rating. El Paso Corp (NYSE:EP), Williams Companies (NYSE:WMB) and Spectra Energy (NYSE:SE) were initiated with Outperform ratings and CenterPoint Energy (NYSE:CNP) and AGL Resources (NYSE:ATG) ATG were assumed with Market Perform ratings.
  • Friedman Billings believes Aeropostale (NYSE:ARO) has an impressive back-to-school floorset and that momentum should carry into the fall. Additionally, the firm, which initiated shares with an Outperform rating and $38 target, expects the company to buyback shares.
  • Thomas Weisel believes ImClone (NASDAQ:IMCL) is attractively valued as Erbitux is positioned to capitalize on a number of label-expanding opportunities and that concerns of KRAS-related revenue loss in colorectal cancer and the clinical utility of FLEX lung cancer data are overstated. Shares were assumed with an Overweight rating and $50 target.
OTHER INITIATIONS:

Symbol Lookup
IndexesChangePrice
DJIA+32.9612,834.19
NASDAQ+13.112,916.99
S&P 500+4.991,347.63

Last updated: February 13, 2012: 10:58 AM

Hot Stocks

General Electric

18.955+0.08(+0.42)

Alcoa

10.30+0.01(+0.10)

Apple Inc

499.08+5.66(+1.15)

Google Inc 'A'

611.22+5.31(+0.88)

Bank of America

8.225+0.155(+1.92)

Wal-Mart Stores

61.91+0.01(+0.02)

Exxon Mobil Corp

83.955+0.155(+0.18)

Ford

12.53+0.09(+0.72)

Citigroup

33.40+0.475(+1.44)

IBM

192.07-0.35(-0.18)

Yahoo

16.085-0.055(-0.34)

Starbucks

49.02+0.20(+0.41)

Microsoft

30.48-0.015(-0.05)

Home Depot

45.66+0.33(+0.73)

DailyFinance Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

Page Loaded in 1329148730767 ms.